Allogenic donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
Commonly known or available as Allogenic donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells - DrugBank Accession Number
- DB15731
- Background
ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients. These cells are CD362 enriched umbilical cord-derived mesenchymal stem cells (UC-MSCs); UC-MSCs share stemness markers with both embryonic stem cells (ESCs) and adult mesenchymal stem cells (MSCs); this feature allows them to be hypoimmunogenic and non-inducible for tumorigenesis.
Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties. Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Cell transplant therapies
Other cell transplant therapies - Synonyms
- Allogeneic donor CD362 enriched human umbilical cord-derived mesenchymal stromal cells
- ORBCEL C™
- Orbcel-C
- REALIST ORBCEL-C
- External IDs
- Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
The mesenchymal stem cells (MSCs) of ORBCEL-C™ act through release of factors which reduce inflammatory responses, promote blood vessel formation, and have the ability to demonstrate immunomodulatory effects.
Allogeneic UC-MSCs are also being investigated in orthopedic applications for cartilage and bone regeneration; these UC-MSCs are a valuable allogeneic source of cells as these cells are from a discarded material with virtually unlimited availability. Specifically to orthopedics, UC-MSCs have potential for treatment of chondral and osteochondral lesions, and bone defects as a universal off-the-shelf product.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Marmotti A, Mattia S, Castoldi F, Barbero A, Mangiavini L, Bonasia DE, Bruzzone M, Dettoni F, Scurati R, Peretti GM: Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells as a Potential Source for Cartilage and Bone Regeneration: An In Vitro Study. Stem Cells Int. 2017;2017:1732094. doi: 10.1155/2017/1732094. Epub 2017 Nov 16. [Article]
- de Witte SFH, Merino AM, Franquesa M, Strini T, van Zoggel JAA, Korevaar SS, Luk F, Gargesha M, O'Flynn L, Roy D, Elliman SJ, Newsome PN, Baan CC, Hoogduijn MJ: Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. Stem Cell Res Ther. 2017 Jun 8;8(1):140. doi: 10.1186/s13287-017-0590-6. [Article]
- Alfaifi M, Eom YW, Newsome PN, Baik SK: Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 2018 Jun;68(6):1272-1285. doi: 10.1016/j.jhep.2018.01.030. Epub 2018 Feb 7. [Article]
- Zakrzewski W, Dobrzynski M, Szymonowicz M, Rybak Z: Stem cells: past, present, and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68. doi: 10.1186/s13287-019-1165-5. [Article]
- Technologies [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1, 2 Active Not Recruiting Treatment Autoimmune Hepatitis / Sclerosing Cholangitis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 11, 2020 19:17 / Updated at August 13, 2020 07:02